Wang Zhenguang, Yang Guangjie, Nie Pei, Fu Junhua, Wang Xufu, Liu Dan
PET/CT Room, the Affiliated Hospital of Qingdao University Medical College, Qingdao University, Qingdao, China.
PLoS One. 2013 Aug 16;8(8):e74327. doi: 10.1371/journal.pone.0074327. eCollection 2013.
Based on practice guideline of "management of hepatocellular carcinoma (HCC): update" published by American Association for the Study of Liver Diseases (AASLD) and "Barcelona Clinic Liver Cancer staging system (BCLC)," this study investigated how to enroll the optimal VX2 liver tumor model for HCC researches by dynamically observing the biological progression of the tumor.
Thirty-two healthy New Zealand white rabbits were implanted VX2 liver tumor by cell suspension method (n=24) and tissue fragment method (n=8). All the rabbits underwent CT scans on day 7, 14, 21 and 28 after implantation to observe the size of the tumors, the time when metastases and ascites occurred and the survival time. Appropriate intervention times were estimated corresponding to different clinical HCC stages by using tumor diameter-time curve.
The VX2 liver tumors grew rapidly within 28 days after implantation. And the tumors in the cell suspension group grew faster than those of the tissue fragment group. The appropriate intervention time corresponding to very early stage, early stage and intermediate stage were <11 days, 11-16.9 days and >16.9 days, respectively in the cell suspension group, and <19.9 days, 19.9-25.5 days and >25.5 days, respectively in the tissue fragment group.
Preclinical animal research needs to improve on different levels to yield best predictions for human patients. Researchers should seek for an individualized proposal to select optimal VX2 liver tumor models for their experiments. This approach may lead to a more accurate determination of therapeutic outcomes.
基于美国肝病研究协会(AASLD)发布的《肝细胞癌(HCC)管理:更新》实践指南以及“巴塞罗那临床肝癌分期系统(BCLC)”,本研究通过动态观察肿瘤的生物学进展,探讨如何为HCC研究招募最佳的VX2肝肿瘤模型。
32只健康的新西兰白兔,采用细胞悬液法(n = 24)和组织块法(n = 8)植入VX2肝肿瘤。所有兔子在植入后第7、14、21和28天进行CT扫描,观察肿瘤大小、转移和腹水出现的时间以及生存时间。利用肿瘤直径-时间曲线,针对不同临床HCC分期估算合适的干预时间。
VX2肝肿瘤在植入后28天内迅速生长。细胞悬液组的肿瘤生长速度比组织块组快。细胞悬液组中,对应极早期、早期和中期的合适干预时间分别为<11天、11 - 16.9天和>16.9天;组织块组中,对应极早期、早期和中期的合适干预时间分别为<19.9天、19.9 - 25.5天和>25.5天。
临床前动物研究需要在不同层面进行改进,以便对人类患者做出最佳预测。研究人员应寻求个性化方案,为其实验选择最佳的VX2肝肿瘤模型。这种方法可能会更准确地确定治疗结果。